Interventional Glaucoma

This year's Shaffer-Hetherington-Hoskins Lecture keynote speaker Joseph Caprioli, MD, focuses on the phenotypes of primary open-angle glaucoma with Ophthalmology Times®' David Hutton at Glaucoma 360.

During the Glaucoma 360 New Horizons Forum, the spotlight was cast upon sustained release injectables, including innovations that have been flourishing over the past year despite, or perhaps because of, a continuing worldwide pandemic.

Robert L. Stamper, MD, speak with Ophthalmology Times®' David Hutton to discuss his presentation at the Glaucoma 360 event in San Francisco, where he presented an update on OCT-Angiography and its role in detecting the density of the capillaries in the macula.

The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.

Ranya Habash, MD, medical director of Technology Innovation, assistant professor of Clinical Ophthalmology at Bascom Palmer Eye Institute, University of Miami in Miami, Florida, offers a preview of her New Horizons keynote speech on "The future of eye care: science fiction to science fact."

Ora Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, speak with Ophthalmology Times®' Sheryl Stevenson to discuss some of the cutting-edge advancements in therapies and diagnostics for the treatment of glaucoma patients.

Glaucoma 360 is being held at the Grand Hyatt San Francisco at Union Square, and the meeting brings together celebration, innovation, and education in its efforts to eradicate glaucoma, with the Gala serving as the traditional kickoff of the event.

Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times®' Sheryl Stevenson on what attendees can expect from this year's annual meeting.

A University of Montréal Hospital Research Center team reveals the fine mechanisms behind the major vascular defects observed in glaucoma patients and identifies new therapeutic targets.

The 3-month study will assess the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution.

A team of investigators has conducted ocular pharmacokinetic studies, including metabolism, providing valuable information for ocular drug development.

Cleveland Eye Bank Foundation (CEBF) will feature nine researchers from three eye institutions on February 15, from 3 to 5 pm Eastern, for its second annual virtual vision research symposium.

Physicians find that additional treatment is not required for many patients.

The pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US, has received positive feedback from glaucoma surgeons involved in the trial.

Marking Glaucoma Awareness Month this month, Bausch + Lomb and the Glaucoma Research Foundation have released key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma.

The acquisition brings the Hydrus Microstent into Alcon’s global surgical portfolio. The company will leverage its global footprint and leadership in ophthalmology to drive future growth, bringing the device to more patients worldwide.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

Ahmad Aref, MD, and Paul Singh, MD, offer a recap of their EyeCon 2021 presentation.

The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.

PRS can modify disease outcomes due to other genes, such as MYOC.

Felipe Medeiros, MD, presents results from a phase 3 clinical extension study of the bimatoprost implant that found patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fiends.

Investigators find that mutations could lead to early treatment intervention.

Three cases demonstrate value of new tools, technology for surgeons.

Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.

Changes are resulting in better outcomes for patients with glaucoma.

Yoshihiro Yonekawa, MD, reports on the findings of an investigation looking at the prevalence of endophthalmitis following minimally invasive glaucoma surgery.

Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.

Speed the return to baseline visual acuity—and make your patients happy.

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.